After an acute ischemia/reperfusion of the rat retina, the activation of cytotoxic proteases, including calpain, results in necrosis and apoptosis of retinal ganglion cells resulting in their degeneration. Using a systemically administered calpain inhibitor that crosses the blood-retinal barrier would provide for novel systemic intervention that protects the retina from acute injury and loss of function. Herein, we study a novel calpain peptide inhibitor, cysteic-leucyl-argininal (CYLA), in an in-vivo rat model of retinal ischemia to determine functional protection using electroretinography. The CYLA prodrug was administered intraperitoneally before and/or after ischemia-reperfusion at concentrations of 20-40 mg/kg. We found that administering 20 mg/kg of CYLA only after ischemia provides significant preservation of retinal function. NeuroReport 22:633-636
Introduction
Ischemia-reperfusion injury involves many signaling mechanisms resulting in necrotic and apoptotic cell death. These injuries are characterized by both retinal ganglion and inner nuclear cell death. Evidence suggests that strategies that target multiple cell death pathways are potential therapeutic agents that protect the retina from this progressive neurodegenerative disease [1, 2] . A strategy that targets a final common pathway, such as calpain inhibitors, offers the potential for greater therapeutic benefit for ischemia-reperfusion injury as well as for other retinal degenerative diseases.
Calpains belong to a family of calcium-dependent cysteine proteases in which there are at least 14 different members [3] . Aberrant activation of this enzyme promotes the breakdown of kinases, phosphatases, transcription factors, and the proteolysis of cytoskeletal proteins, including a-spectrin, all of which contribute to neuronal cell death [4] .
The role of calpain in neuronal cell death is thought to occur by antinecrotic and antiapoptotic mechanisms [5, 6] . Calpains may be activated by an increased influx of Ca + ions that occurs during ischemia, which contributes to necrotic cell death [7] . Furthermore, activation of calpain is generally associated with DNA degradation rather than condensation, a feature associated with necrosis [8] . Alternatively, calpain is closely associated with apoptosis through the caspase activation pathway. For example, caspase-3 activation from proapoptotic signaling degrades calpastatin, an endogenous inhibitor of calpain [9] . Calpain activates caspase-3, demonstrating that the apoptotic pathway is associated with increased calpain activity [10] . Further studies suggest that calpain acts by activating caspase-12 through direct proteolytic cleavage [11] . Calpain inhibition would therefore provide an ideal treatment because of this final common pathway between the necrotic and apoptotic cell death systems.
A difficulty posed by calpain inhibitors in in-vivo models is the inability of many of these drugs to penetrate the blood-brain barrier (BBB) and the blood-retinal barrier [12] . The calpain inhibitor prodrug, cysteic-leucylargininal (CYLA), evaluated in this study, is synthesized by attaching the carboxyl group of cysteic acid (a-aminob-sulfo-propionic acid) to leucyl-argininal diethyl acetal. Cysteic acid shares structural similarities with taurine (2-aminoethanesulfonic acid), a b-amino acid that is transported through cell membranes by an Na + -dependent and Cl --dependent transporter (TauT/Slc6a6) [12] that penetrates the BBB and acts as a competitive inhibitor of the taurine transport mechanism [13] . Furthermore, taurine is the most abundant free amino acid in the retina [14] . It is approximately 100 times greater in concentration compared with that of the serum [15] . The CYLA prodrug is a diethyl acetal and has been documented as an inactive calpain inhibitor in vitro but is thought to be converted into the active inhibitor in vivo [16] .
Materials and methods
Preparation and application of CYLA The CYLA prodrug, a diethyl acetal, was a gift from Dr Alfred Stracher, and its activation in vitro was previously described [16] . The CYLA prodrug was stored in a 41C refrigerator, and was dissolved in 0.33 ml of PBS immediately prior to its administration intraperitoneally. The doses were administered 1 h before ischemia and 3 h postischemia, or only 3 h postischemia. The quantity of CYLA prodrug used in this study was 3 mg (20 mg/kg) and 6 mg (40 mg/kg)(i.e. 20 or 40 mg/kg of CYLA prodrug were dissolved in 0.33 ml of PBS). These doses of drug were chosen based on correlations to previous studies using the same drug in an in-vivo model [13] . Leupeptin, an active calpain inhibitor, was administered at 40 mg/kg in 0.33 ml of PBS and served as a control due to its lack of CNS barrier permeability relative to the to CYLA prodrug [16] .
Retinal ischemia
All animals were treated in accordance with the State University of New York Downstate Medical Center Animal Care and Use Committee (Protocol Number 06-307-10). Male Sprague-Dawley rats weighing 150-175 g (Taconics, Hudson, New York, USA) were subjected to high intraocular pressure (IOP) that leads to retinal ischemia [2, 17, 18] . In brief, rats are deeply anesthetized with an intramuscular injection of ketamine (40 mg/kg) and xylazine (2.5 mg/kg). The anterior chamber of the right eye was cannulated using a 27-gauge needle and attached by silastic tubing to an infusion of sterile 0.9% saline. Under direct vision, the needle tip was placed within the anterior chamber and the corneal puncture site was sealed with cyanoacrylate cement. IOP was raised to 120 mmHg by elevating the saline container to exceed systemic arterial blood pressure, for 45 min, a duration found previously to provide ischemia that causes physiological irreversible cell damage [1, 2] . Animals were kept normothermic at 37 ± 0.51C with a rectal probe and a heating pad during the procedure. Whitening of the iris and loss of the red reflex of the retina confirmed retinal ischemia. After completion of the target period of ischemia, the needle was withdrawn and the IOP normalized. The contralateral eye of each animal served as a nonischemic control. One drop of gentamicin ophthalmic solution was applied topically to the right eye before and after cannulating the anterior chamber.
Electroretinography
The procedures used were those that we have previously reported [2, 19] . In brief, animals were anesthetized and their pupils were dilated with tropicamide and cyclomydril. Platinum electroencephalographic electrodes were placed on the corneas, and the a-wave and b-wave were identified after presenting full-field stroboscopic flashes at the rate of 1.0/s at a distance of 15 cm. Electroretinograms (ERGs) measurements were taken before the ischemic insult to determine the baseline and again before enucleation at 7 days postischemia. ERG measurements of the right and left eyes were always taken together, with the left eye serving as the nonischemic control.
All data are expressed as mean ± standard error of the mean (SEM). ERG data were analyzed with analysis of variance followed by Dunnett's test. For all comparisons P value less than 0.05 was regarded as statistically significant.
For all studies, investigators were blinded to treatment during surgery, data acquisition, and analysis.
Results

Electroretinograms
Previous studies have demonstrated that maximum changes in ERG occur 7 days postischemia [1, 18] . This ERG data were collected 7 days after 45 min of retinal ischemia. The CYLA prodrug given intraperitoneally significantly preserved retinal function compared with the vehicle-treated rats as there was significant preservation of the b-wave in the treated animals ( Fig. 1 ). We observed that compared with the PBS control that exhibited only 17% preservation of retinal function (SEM ± 3.0), as represented by the b-wave, the CYLA prodrug preserved 43.0% of function (SEM ± 6.2, P < 0.05) when one dose of the drug was administered (20 mg/kg) 3 h postischemia. We also observed that when the drug was administered twice at the same dosage (20 mg/kg), 1 h before ischemia and 3 h postischemia, there was 39.4% preservation of retinal function represented by the b-wave. Furthermore, there appeared to be little difference between the animals treated with two doses of the drug (20 mg/kg), 1 h preischemia and 3 h postischemia, compared with the animals treated with one dose of the drug (20 mg/kg) 3 h postischemia. Although the groups treated with 40 mg/kg of the drug did not show a statistically significant benefit when compared with the control group (P > 0.05), there still appeared to be little difference in retinal preservation of function compared with the animals treated with 20 mg/kg of drug (P > 0.05). Leupeptin, a calpain inhibitor that is unable to cross the BBB, appeared not to protect the retinal tissue against ischemia as it preserved retinal function by only 21.8% (SEM ± 3.3, P > 0.05) when compared with the control group (Fig. 2 ).
Discussion
In this study, we have used a blood-central nervous system barrier-permeable calpain inhibitor, CYLA, in an in-vivo model to demonstrate that postischemic inhibition of calpain significantly reduces retinal cell death and improved retinal function after an acute ischemiareperfusion. The significant protective effect of this inhibitor provides evidence supporting a role for calpain in retinal dysfunction after retinal ischemia.
In retinal ischemia, cell death is in part due to (a) an increase in glutamate from damaged synapses activating N-methyl-D-aspartate and a-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor activation as well as (b) the activation of voltage-dependent calcium channels causing a Ca ++ influx and activation of Ca ++dependent processes [20, 21] . Calpain has been implicated in the proteolysis of the Na + /Ca + exchanger, resulting in a reduced expulsion of the Ca ++ ions. This results in an ion imbalance that favors a Ca + influx, which leads to the activation of Ca ++ -dependent calpain [22] . Aberrant activation of this enzyme promotes the breakdown of kinases, phosphatases, transcription factors, and the proteolysis of cytoskeletal proteins all of which contribute to neuronal cell death [3] . Thus, using calpain inhibitors can prevent many processes involved in neuronal cell homeostasis, integrity, plasticity, and repair.
Of note is the fact that the CYLA prodrug was effective when it was administered 3 h postischemia. An additional dose administered preischemia provided no additional benefit. This further supports the fact that the mechanism of action of calpain is of postischemic inhibition of proteolysis. This too is of clinical importance as calpain has been shown to protect neuronal cells in brain tissue [21] as well and therefore may be of importance in conditions such as stroke and traumatic brain injury. Further studies will have to be conducted to determine how long after an ischemic event the calpain inhibitor would still be effective. In addition, the dose-response curve should be determined.
Most literature that has used calpain inhibitors have focused either on single organ in-vitro studies [23] or used a calpain inhibitor infusion over time [24, 25] . This study focuses on preservation of neuronal cell death following an acute ischemia after a single injection of a calpain inhibitor. Of interest is the fact that leupeptin, an active calpain inhibitor, showed no functional preservation when administered intraperitoneally, whereas the inactivated calpain inhibitor, CYLA prodrug, showed significant functional preservation suggesting that the prodrug is converted to the active drug in vivo. This is as seen in other in-vivo studies [16] and emphasizes the clinical importance of such a drug.
Conclusion
This study demonstrates that a calpain inhibitor can improve functional outcome after retinal ischemia. In addition, the fact that the drug was administered systemically and was able to penetrate the blood-central nervous system barrier and protect the retina from damage is of clinical relevance.
